Clinical Trial Update: Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating cabozantinib in combination with PD-1 and CTLA-4 inhibitors for metastatic soft tissue sarcoma; the study is currently not recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• cabozantinib (cabozantinib)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Metastatic Soft-tissue Sarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING